Misplaced Pages

This is the current revision of this page, as edited by JWBE (talk | contribs) at 17:42, 7 September 2024 (removed Category:Chloroarenes; added Category:4-Chlorophenyl compounds using HotCat). The present address (URL) is a permanent link to this version.

Vorozole

Clinical data
Other names	R-76713; Rizivor
ATC code	L02BG05 (WHO)
Pharmacokinetic data
Bioavailability	Very high
Metabolism	Hepatic
Elimination half-life	8 hours
Identifiers
IUPAC name 6--1-methylbenzotriazole
CAS Number	129731-10-8
PubChem CID	6918191
ChemSpider	5293402
UNII	1E2S9YXV2A
KEGG	D03786
ChEMBL	ChEMBL224060
CompTox Dashboard (EPA)	DTXSID20156230
Chemical and physical data
Formula	C16H13ClN6
Molar mass	324.77 g·mol
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1)(c2ccc3nnn(c3c2)C)n4ncnc4
(what is this?)  (verify)

Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is a triazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.

References

1. Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Research and Treatment. 49. 49 (Suppl 1): S59-65, discussion S73-7. doi:10.1023/a:1006052923468. PMID 9797019. S2CID 28231447.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Aromatase inhibitors
• Benzotriazoles
• 4-Chlorophenyl compounds
• Triazoles
• Antineoplastic and immunomodulating drug stubs